Tetra Tech Awarded Contract to Provide Advanced Water Treatment Solutions in Florida
PASADENA, Calif.--(BUSINESS WIRE)-- Tetra Tech, Inc. (NASDAQ: TTEK), a leading provider of high-end consulting and engineering services in water, environment, and sustainable infrastructure, announced today that the City of Cape Coral, Florida, selected Tetra Tech to provide engineering design and technical services to expand its North Reverse Osmosis Water Treatment Plant.
Tetra Tech will provide advanced water treatment solutions to expand the plant's production capacity by 50 percent and double existing ground storage reservoir capacity. The $60 million expansion project will incorporate innovative technologies for energy recovery and process optimization of the existing treatment system to support the City in providing reliable service for its growing population while mitigating pressure on local aquifers. Tetra Tech engineers and technical specialists will provide services to transform brackish groundwater into high-quality drinking water, including engineering design, preparation of technical plans and specifications, permitting, and testing and commissioning.
'For almost 40 years, Tetra Tech has provided innovative water treatment solutions to support the resilience of communities throughout Florida,' said Dan Batrack, Tetra Tech Chairman and CEO. 'We look forward to continuing to solve critical water supply challenges, support regional growth, and deliver value to the City of Cape Coral and its residents.'
About Tetra Tech
Tetra Tech is the leader in water, environment and sustainable infrastructure, providing high-end consulting and engineering services for projects worldwide. With 30,000 employees working together, Tetra Tech provides clear solutions to complex problems by Leading with Science ® to address the entire water cycle, protect and restore the environment, design sustainable and resilient infrastructure, and support the clean energy transition. For more information about Tetra Tech, please visit tetratech.com or follow us on LinkedIn and Facebook.
Any statements made in this release that are not based on historical fact are forward-looking statements. Any forward-looking statements made in this release represent management's best judgment as to what may occur in the future. However, Tetra Tech's actual outcome and results are not guaranteed and are subject to certain risks, uncertainties and assumptions ("Future Factors"), and may differ materially from what is expressed. For a description of Future Factors that could cause actual results to differ materially from such forward-looking statements, see the discussion under the section "Risk Factors" included in the Company's Form 10-K and Form 10-Q filings with the Securities and Exchange Commission.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 minutes ago
- Yahoo
Globalink Investment Inc. Announces Extension of the Deadline to Complete a Business Combination to July 9, 2025
New York, NY , June 06, 2025 (GLOBE NEWSWIRE) -- Globalink Investment Inc. (OTC Pink: GLLI, GLLIW, GLLIR, GLLIU) ('' or the ''), a special purpose acquisition company, announced today that on June 5, 2025, it caused to be deposited $0.15 per public share, totaling $10,890.15 (the '') into its trust account (the '') with Continental Stock Transfer and Trust Company ('') to extend the deadline to complete its initial business combination from June 9, 2025 to July 9, 2025. The extension is the twenty-fourth extension since the consummation of the Company's initial public offering on December 9, 2021, and the first of up to six extensions permitted under the Company's governing documents currently in effect. About Globalink Investment Inc. Globalink is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. Although there is no restriction or limitation on what industry or geographic region, Globalink intends to pursue targets in North America, Europe, Southeast Asia, and Asia (excluding China, Hong Kong and Macau) in the medical technology and green energy industry. Cautionary Statement Regarding Forward-Looking Statements Certain statements in this press release are 'forward-looking statements' within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. In some cases, forward-looking statements can be identified by terminology such as 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'plan,' 'anticipate,' 'intend,' 'believe,' 'estimate,' 'predict,' 'potential,' 'outlook,' 'guidance' or the negative of those terms or other comparable terminology. These statements are based on the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties. Because these forward-looking statements involve risks and uncertainties, there are important factors that could cause future events to differ materially from those in the forward-looking statements, many of which are outside of the Company's control. These factors include, but are not limited to, a variety of risk factors affecting the Company's business and prospects, see the section titled 'Risk Factors' in the Company's annual report on Form 10-K for the fiscal year ended December 31, 2024 filed with the SEC on March 25, 2025 and the prospectus filed with the SEC on December 6, 2021 and subsequent reports filed with the SEC, as amended from time to time. Any forward-looking statements are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Globalink Contact: Say Leong LimGlobalink Investment +6012 405 0015Email: limsayleong@
Yahoo
10 minutes ago
- Yahoo
HubSpot, Inc. (HUBS): A Bull Case Theory
We came across a bullish thesis on HubSpot, Inc. (HUBS) on Compouding Your Wealth's Substack. In this article, we will summarize the bulls' thesis on HUBS. HubSpot, Inc. (HUBS)'s share was trading at $578.25 as of 29th May. HUBS's forward P/E was 61.73 according to Yahoo Finance. A person using a laptop with a blue background showing the software platform's user inteface. HubSpot reported strong financial results for Q1 2025, with revenue reaching $714.1 million, a 15.7% increase year-over-year and 20.8% quarter-over-quarter growth, surpassing estimates by 2.3%. Subscription revenue, which makes up nearly 98% of total revenue, grew by the same rate, highlighting continued customer demand for its core offerings. While gross margin declined slightly by 0.7 percentage points to 83.9%, and operating margin dropped by 0.9 points to 14%, free cash flow margin improved modestly to 17.1%. Net margin was negative 3.1%, reflecting a 4-point decrease from the prior year, largely influenced by non-GAAP adjustments and timing of certain expenses. Earnings per share of $1.78 exceeded expectations by 1.7%. Key metrics such as deferred revenue and remaining performance obligations showed significant growth, up nearly 20% and 37% respectively, underscoring strong future revenue visibility. Billings rose by 19.6%, though average revenue per customer declined slightly by 3.6%, signaling some pressure on pricing or customer mix. Customer count increased by 19.1% to over 258,000. On the operational side, sales and marketing efficiency improved with S&M expense as a percentage of revenue falling by 1.6 points, while R&D and G&A expenses rose modestly as a share of revenue. The company highlighted its rapid product innovation with over 200 new features released, particularly embedding AI across its platform and expanding enterprise capabilities. AI-powered tools like Customer Agent have driven measurable improvements in sales and support efficiency. HubSpot raised its full-year revenue guidance to approximately $3.04 billion, projecting continued growth fueled by a combination of seat expansion and consumption-based AI monetization, while maintaining a cautious view on macroeconomic uncertainty. For a comprehensive analysis of another standout stock covered by the same author, we recommend reading our summary of this bullish thesis on Shopify Inc. (SHOP). HubSpot, Inc. (HUBS) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 61 hedge fund portfolios held HUBS at the end of the first quarter which was 73 in the previous quarter. While we acknowledge the potential of HUBS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey.
Yahoo
22 minutes ago
- Yahoo
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, June 06, 2025--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer's Board of Directors approved the grant, effective June 5th, 2025, to three non-executive employees of non-qualified stock option awards to purchase up to an aggregate of 69,875 shares of the Company's common stock under the Gossamer Bio, Inc. 2023 Employment Inducement Incentive Award Plan ("2023 Inducement Plan"). The awards were granted as an inducement material to the employees entering into employment with Gossamer in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $1.26 per share, which is equal to the closing price of Gossamer's common stock as reported by The Nasdaq Global Select Market on June 5th, 2025. The options have a ten-year term and will vest over four years, with 25% vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the shares vesting in a series of 36 successive monthly installments thereafter, subject to the employees' continued employment with Gossamer on such vesting dates. The options are subject to the terms and conditions of the 2023 Inducement Plan and the terms and conditions of a stock option agreement covering the grants. About Gossamer Bio Gossamer Bio is a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Its goal is to be an industry leader in, and to enhance the lives of patients living with, pulmonary hypertension. View source version on Contacts For Investors and Media: Bryan Giraudo, Chief Operating Officer and Chief Financial OfficerGossamer Bio Investor Relationsir@ Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
